Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR‐mutation positive non‐small cell lung cancer

2020 ◽  
Vol 45 (4) ◽  
pp. 652-659
Author(s):  
Hayato Yokota ◽  
Kazuhiro Sato ◽  
Sho Sakamoto ◽  
Yuji Okuda ◽  
Mariko Asano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Gefitinib Treatment

Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment

2012 ◽  
Vol 50 (3) ◽  
pp. 117-121 ◽  
Author(s):  
Sayaka Mochizuki ◽  
Naoki Nishimura ◽  
Akira Inoue ◽  
Koji Murakami ◽  
Toshihiro Nukiwa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Gefitinib Treatment

Association of TP53 mutation status with clinical outcomes stratified by sensitive and non sensitive EGFR mutation, in non-small cell lung cancer (NSCLC).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e19076-e19076
Author(s):  
Saman Ahmed ◽  
Charu Aggarwal ◽  
Rosemarie Mick ◽  
Trisha M Sterlicchi ◽  
Stephan Kadauke ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Cell Lung Cancer ◽  
Tp53 Mutation ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mutation Status

60 Afatinib in EGFR mutation positive advanced non-small cell lung cancer

Lung Cancer ◽  
2016 ◽  
Vol 91 ◽  
pp. S22
Author(s):  
R.S. Davies ◽  
A.E. Brewster ◽  
M.R. Button ◽  
J.F. Lester
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document